Back

Polymicrobial extracellular vesicles reduce the innate immune response of human cystic fibrosis bronchial epithelial cells

Charpentier, L. A.; Barnaby, R.; Roche, C.; Cho, B.-K.; Kaushal, P.; Ah Goo, Y.; Vietje, B.; Taatjes, D.; Ashare, A.; Jean-Pierre, F.; Stanton, B.

2026-04-10 microbiology
10.64898/2026.04.09.717493 bioRxiv
Show abstract

Chronic antibiotic-resistant cystic fibrosis (CF) lung infections are the leading cause of death in adults with CF. Despite advances in highly effective modulator therapies, microbial communities persist in the CF lung. The pathogenesis of CF airway infections can be exacerbated by pathogens such as Pseudomonas aeruginosa, which communicates with primary human bronchial epithelial cells (pHBEC) by secreting bacterial extracellular vesicles (bEVs) that diffuse through mucus and deliver virulence factors, DNA, and RNA to pHBEC. However, most CF lung infections are polymicrobial in nature, and therefore, the contribution of polymicrobial bEVs remains to be determined. By using a polymicrobial culture model representing a pulmotype detected in [~]34% of lung infections in people with CF (pwCF), comprised of P. aeruginosa, Staphylococcus aureus, Streptococcus sanguinis, and Prevotella melaninogenica grown in synthetic sputum medium under anoxia, we report that each bacterial genus in the polymicrobial community secretes bEVs containing proteins and RNAs predicted to promote the establishment of chronic infection by enhancing virulence, biofilm formation, and upregulating the stress response and pro-inflammatory pathways in pHBEC. This response is most pronounced in CF pHBEC. Elexacaftor/Tezacaftor/Ivacaftor (ETI), a highly effective modulator therapy, does not ameliorate the response or return it to WT levels. Bacterial EVs also inhibited ETI CFTR Cl- currents by CF pHBEC. These studies provide insight into why ETI does not eliminate polymicrobial lung infections and a hyperinflammatory lung environment in pwCF. IMPORTANCECystic fibrosis (CF) is a genetic disease characterized by chronic polymicrobial lung infections that, if untreated, are one of the primary causes of death in CF. Elexacaftor/Tezacaftor/Ivacaftor (ETI) has many positive clinical outcomes, but it does not eliminate chronic polymicrobial lung infections or inflammation. Using a new biologically relevant co-culture model, we have demonstrated that bacteria secrete vesicles (bEVs) that contain proteins and RNAs. We observed that these RNA-loaded bEVs are predicted to promote the pathogenesis of chronic CF lung infections by enhancing bacterial virulence and biofilm formation, as well as upregulating the pro-inflammatory response in lung cells. ETI does not ameliorate the response of lung cells to bEVs. Our research will facilitate the development of more effective approaches to eliminate infection and inflammation in CF and other lung diseases characterized by chronic polymicrobial infections and excessive inflammation.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 5%
10.2%
2
mBio
750 papers in training set
Top 2%
8.5%
3
American Journal of Respiratory Cell and Molecular Biology
38 papers in training set
Top 0.1%
6.9%
4
Nature Communications
4913 papers in training set
Top 32%
4.9%
5
eLife
5422 papers in training set
Top 16%
4.9%
6
PLOS Biology
408 papers in training set
Top 1%
4.9%
7
PLOS Pathogens
721 papers in training set
Top 3%
4.4%
8
Journal of Cystic Fibrosis
15 papers in training set
Top 0.1%
3.6%
9
JCI Insight
241 papers in training set
Top 2%
3.3%
50% of probability mass above
10
The Journal of Infectious Diseases
182 papers in training set
Top 2%
2.1%
11
Journal of Clinical Investigation
164 papers in training set
Top 2%
2.1%
12
American Journal of Physiology-Lung Cellular and Molecular Physiology
39 papers in training set
Top 0.2%
1.9%
13
Science Translational Medicine
111 papers in training set
Top 2%
1.8%
14
Disease Models & Mechanisms
119 papers in training set
Top 1.0%
1.8%
15
mSphere
281 papers in training set
Top 3%
1.8%
16
Scientific Reports
3102 papers in training set
Top 57%
1.7%
17
PLOS Genetics
756 papers in training set
Top 8%
1.7%
18
EBioMedicine
39 papers in training set
Top 0.3%
1.7%
19
iScience
1063 papers in training set
Top 14%
1.7%
20
American Journal of Respiratory and Critical Care Medicine
39 papers in training set
Top 0.5%
1.5%
21
Cell Reports
1338 papers in training set
Top 27%
1.3%
22
Life Science Alliance
263 papers in training set
Top 0.7%
1.2%
23
Cell Reports Medicine
140 papers in training set
Top 6%
1.0%
24
ERJ Open Research
44 papers in training set
Top 0.6%
1.0%
25
Molecular Therapy
71 papers in training set
Top 2%
1.0%
26
Journal of Bacteriology
190 papers in training set
Top 0.7%
0.9%
27
Nature Medicine
117 papers in training set
Top 4%
0.9%
28
European Respiratory Journal
54 papers in training set
Top 2%
0.9%
29
Genome Medicine
154 papers in training set
Top 7%
0.8%
30
Cell Host & Microbe
113 papers in training set
Top 4%
0.8%